Abstract: The invention relates to the field of diagnostic immunology. Provided are means and methods for multiparameter cytometry-based leukocyte subsetting, which is advantageously used for the monitoring of the immune status of a subject, and/or for monitoring the effects of an immune modulatory treatment. Provided among others is a reagent composition comprising antibodies conjugated to a detectable label, the conjugated antibodies being directed against the following combination of markers: CD141, HLA-DR, CD16, CD33, CD300e, CD303 and CD14, wherein the antibodies directed against CD300e and CD303 may be conjugated to the same label.

Abstract: The invention relates to methods to evaluate in one single assay the biocompatibility of materials based on the simultaneous determination of the phagocytosis, cell activation and cell death produced by said materials, preferably, in peripheral blood or other human cells and proximal fluids. The invention also relates to a kit to perform the method of the invention.

Abstract: The invention relates to aspartic proteases, and particularly to aspartic proteases for plants. Disclosed are modified plant aspartic proteases, and methods for their manufacture, and uses thereof. Particularly contemplated are the uses of aspartic proteases in clotting milk.

Abstract: Methods and composition, thereof, relate to aspartic proteases, and particularly to aspartic proteases for plants. Disclosed are modified plant aspartic proteases, and methods for their manufacture, and uses thereof. Particularly contemplated are the uses of aspartic proteases in inducing skin desquamation.

Abstract: The invention relates to methods to evaluate in one single assay the biocompatibility of materials based on the simultaneous determination of the phagocytosis, cell activation and cell death produced by said materials, preferably, in peripheral blood or other human cells and proximal fluids. The invention also relates to a kit to perform the method of the invention.

Abstract: The invention relates to the use of carbon monoxide (CO) to inhibit the gastrointestinal side effects caused by non-steroidal anti-inflammatory drugs (NSAIDs) and/or alcohol.

Abstract: The invention relates to aspartic proteases, and particularly to aspartic proteases for plants. Disclosed are modified plant aspartic proteases, and methods for their manufacture, and uses thereof. Particularly contemplated are the uses of aspartic proteases in inducing skin desquamation.

Abstract: The invention relates to aspartic proteases, and particularly to aspartic proteases for plants. Disclosed are modified plant aspartic proteases, and methods for their manufacture, and uses thereof. Particularly contemplated are the uses of aspartic proteases in clotting milk.

Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.

Abstract: The invention relates to the use of carbon monoxide (CO) to inhibit the gastrointestinal side effects caused by non-steroidal anti-inflammatory drugs (NSAIDs) and/or alcohol.

Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.

Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.

Abstract: The present invention relates to molybdenum carbonyl complexes useful for inhibiting tumor necrosis factor (TNF) production and for treating inflammatory diseases.

Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.

Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.

Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.

Abstract: A ferromagnetic shield material having a minimized anisotropic magneto-resistance effect permits the use of a combined shield/electrical lead for magneto-resistive read elements. The shields/electrical leads may therefore be placed closer together, maximizing the recording density that may be read by a magnetic recording head using a read element having such shields/leads.

Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.

Abstract: An integrated read/write perpendicular recording head facilitates the use of magnetic storage media having a high magnetic recording density and high data rates. The use of a perpendicular write portion provides adequate space between the main and opposing poles for a read element and associated electrical contacts therebetween. The use of a differential dual spin valve as a read element eliminates the need for magnetic shielding of the read element. Such a structure permits the read element and main write pole to be close together, thereby minimizing seek time, and permitting rapid transition from read to write operations, and vice versa.